Table 4.
Assessment of therapuetic efficiency by TrxR, CEA, AFP, and CA19-9 and their combinations in distinguishing MLC from PLC patients in the CUP and CRP group.
| Tumor markers | Liver cancer patients after chemotherapy | ||||||
|---|---|---|---|---|---|---|---|
| AUC (95%CI) | SEN% | SPE% | PPV% | NPV% | PLR | NLR | |
| CUPs for differences between PLCs and MLCs | |||||||
| TrxR | 0.615 (0.508–0.721) | 59.02 | 71.43 | 67.38 | 63.54 | 2.07 | 1.74 |
| AFP | 0.529 (0.417–0.642) | 100.00 | 14.29 | 53.85 | 100.00 | 1.17 | — |
| CEA | 0.568 (0.459–0.678) | 81.97 | 36.73 | 56.44 | 67.07 | 1.30 | 2.04 |
| CA19-9 | 0.540 (0.431–0.648) | 59.02 | 53.06 | 55.70 | 56.42 | 1.26 | 1.29 |
| CEA + CA19-9 + AFP | 0.618(0.513–0.724) | 83.61 | 38.78 | 57.73 | 70.29 | 1.37 | 2.37 |
| CEA + CA19-9 + AFP + TrxR | 0.683 (0.583–0.783) | 62.30 | 69.39 | 67.05 | 64.79 | 2.03 | 1.84 |
| CRPs for differences between PLCs and MLCs | |||||||
| TrxR | 0.605 (0.538–0.718) | 88.82 | 35.56 | 57.95 | 76.08 | 1.38 | 3.18 |
| AFP | 0.522 (0.456–0.587) | 31.18 | 92.59 | 80.80 | 57.36 | 4.21 | 1.35 |
| CEA | 0.728 (0.672–0.785) | 57.65 | 78.52 | 72.85 | 64.96 | 2.68 | 1.85 |
| CA19-9 | 0.631 (0.567–0.695) | 64.12 | 60.00 | 61.58 | 62.58 | 1.60 | 1.67 |
| CEA + CA19-9 + AFP | 0.763 (0.771–0.816) | 62.94 | 79.26 | 75.21 | 68.14 | 3.03 | 2.14 |
| CEA + CA19-9 + AFP + TrxR | 0.705 (0.645–0.766) | 80.59 | 57.78 | 65.62 | 74.85 | 1.91 | 2.98 |
SPE: specificity; SEN: sensitivity; NPV: negative predictive value; PPV: positive predictive value;NLR: negative likelihood ratio. PLR: positive likelihood ratio.